You are here

Böbrek Nakli Hastalarında Plazmaferez Tedavisi

Share
Plasmapheresis Therapy in Renal Transplant Patients

Journal Name:

Publication Year:

Volume:

Number:

Sayfa Aralığı:: 
1-6

Publication Language:

Abstract (Original Language): 
Klinik pratikte, plazmaferez tedavisi dolaşan immünkompleksler, endotoksinler ve kolesterol içeren lipoproteinler gibi büyük molekül ağırlıklı maddeleri plazmadan temizlemek için kullanılmaktadır. Plazmaferez tedavisi romatoloji, onkoloji, dermatoloji ve nefrolojide belli başlı bazı hastalıkların tedavisinde fayda sağlamaktadır. Son dönem böbrek yetmezliğinin en seçkin tedavi yöntemi böbrek naklidir. Böbrek nakli sonrası dönemde gelişen akut-kronik rejeksiyonlar ve primer böbrek hastalığının nüksü greft sağ kalım süresini kısaltmaktadır. Plazmaferez tedavisi böbrek nakli hastalarında da transplant öncesi ve sonrası dönemde; ABO uyuşmazlığı, yüksek sensitize hastalar, akut-kronik humoral rejeksiyon, tekrarlayan glomerülonefrit ve trombotik mikroanjiyopati durumlarında kullanılabilir.
Abstract (2. Language): 
In clinical practice, plasmapheresis is utilized to remove circulating immune complexes, endotoxins and high molecular weight molecules such as lipoproteins containing cholesterol. It is useful in certain diseases in rheumatology, oncology, dermatology and nephrology. Renal transplantation is the most exclusive treatment modality in end stage renal failure. Acute and chronic rejections along with the recurrence of the primary kidney disease at the post-transplant period shorten graft survival. Plasmapheresis treatment can be used both at the pre- and post-transplant period in cases of ABO incompatibility, highly sensitized patients, acute and chronic rejections, recurring glomerulonephritis and thrombotic microangiopathies.

Keywords (Original Language):

DOI: 
DOI 10.5262/tndt.2013.1001.01

REFERENCES

References: 

1. Sanchez AP, Ward DM: Therapeutic apheresis for renal disorders.
Semin Dial 2012; 25: 119-131
2. Pusey CD, Levy JB: Plasmapheresis in immunologic renal disease.
Blood Purif 2012; 33: 190-198
3. Dittrich E, Schmaldienst S, Derfler K: Plasma exchange and
immunoadsorption. Wien Klin Wochenschr 2007; 119: 39-53
4. Fukatsu A, Tanaka Y, Iehara N: Double filtration plasmapheresis for
therapy of hyperlipidemia. Nihon Rinsho 2004; 62: 595-598
5. Hershko AY, Naparstek Y: Removal of pathogenic autoantibodies
by immunoadsorption. Ann N Y Acad Sci 2005; 1051: 635-646
6. Ichimaru N, Takahara S: Japan’s experience with living-donor
kidney transplantation across ABO barriers. Nat Clin Pract Nephrol
2008; 4: 682-692
7. Shin M, Kim SJ: ABO Incompatible kidney transplantation-current
status and uncertainties. J Transplant 2011; 2011: 970421
8. Flint SM, Walker RG, Hogan C, Haeusler MN, Robertson A, Francis
DM, Millar R, Finlay M, Landgren A, Cohney SJ: Successful ABOincompatible
kidney transplantation with antibody removal and
standard immunosuppression. Am J Transplant 2011; 11: 1016-1024
9. Higgins R, Lowe D, Hathaway M, Lam FT, Kashi H, Tan LC, Imray
C, Fletcher S, Chen K, Krishnan N, Hamer R, Zehnder D, Briggs D:
Double filtration plasmapheresis in antibody-incompatible kidney
transplantation. Ther Apher Dial 2010 ; 14: 392-399
10. Biglarnia AR, Nilsson B, Nilsson Ekdahl K, Tufveson G, Nilsson
T, Larsson E, Wadström J: Desensitization with antigen-specific
immunoadsorption interferes with complement in ABO-incompatible
kidney transplantation. Transplantation 2012; 93: 87-92
11. Tobian AA, Shirey RS, Montgomery RA, Ness PM, King KE:
The critical role of plasmapheresis in ABO-incompatible renal
transplantation. Transfusion 2008; 48: 2453-2460
12. Tobian AA, Shirey RS, Montgomery RA, Tisch DJ, Ness PM,
King KE: Therapeutic plasma exchange reduces ABO titers to
permit ABO-incompatible renal transplantation. Transfusion 2010;
49:1248-1254
13. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King
KE, Shirey RS, Simpkins CE, Montgomery RA: Plasmapheresis,
CMV hyperimmune globulin, and anti-CD20 allow ABO incompatible renal transplantation without splenectomy. Am J
Transplant 2004; 4: 1315-1322
14. Tydén G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman
I: ABO incompatible kidney transplantations without splenectomy,
using antigen-specific immunoadsorption and rituximab. Am J
Transplant 2005; 5: 145-148
15. Kumlien G, Ullström L, Losvall A, Persson LG, Tydén G: Clinical
experience with a new apheresis filter that specifically depletes
ABO blood group antibodies. Transfusion 2006; 46: 1568-1575
16. Beimler JH, Morath C, Schmidt J, Ovens J, Opelz G, Rahmel A,
Zeier M, Süsal C: Successful deceased-donor kidney transplantation
in crossmatch-positive patients with peritransplant plasma exchange
and Rituximab. Transplantation 2009; 87: 668-671
17. Higgins RM, Bevan DJ, Vaughan RW, Phillips AO, Snowden S,
Bewick M, Scoble JE, Hendry BM: 5-year follow-up of patients
successfully transplanted after immunoadsorption to remove anti-
HLA antibodies. Nephron 1996; 74:53-57
18. Haas M, Böhmig GA, Leko-Mohr Z, Exner M, Regele H, Derfler K,
Hörl WH, Druml W: Peri-operative immunoadsorption in sensitized
renal transplant recipients. Nephrol Dial Transplant 2002 ;17:
1503-1508
19. Lorenz M, Regele H, Schillinger M, Kletzmayr J, Haidbauer B,
Derfler K, Druml W, Böhmig GA: Peritransplant immunoadsorption:
A strategy enabling transplantation in highly sensitized crossmatchpositive
cadaveric kidney allograft recipients. Transplantation 2005;
79: 696-701
20. Wang W, Lıu H, Yın H, Lı XB, Yang XY, Ren L, Hu XP, Wang Y,
Zhang XD: Immunoadsorption in highly sensitized renal transplant
recipients. Zhonghua Yi Xue Za Zhi 2010; 90: 2532-2535
21. Yin H, Hu XP, Li XB, Liu H, Wang W, Ren L, Wang Y, Zhang XD:
Protein A immunoadsorption combined with rituximab in highly
sensitized kidney transplant recipients. Chin Med J (Engl) 2009;
122: 2752-2756
22. Archdeacon P, Chan M, Neuland C, Velidedeoglu E, Meyer J, Tracy
L, Cavaille-Coll M, Bala S, Hernandez A, Albrecht R: Summary of
FDA antibody-mediated rejection workshop. Am J Transplant 2011;
11: 896-906
23. Böhmig GA, Regele H, Exner M, Derhartunian V, Kletzmayr J,
Säemann MD, Hörl WH, Druml W, Watschinger B: C4d-positive
acute humoral renal allograft rejection: Effective treatment by
immunoadsorption. J Am Soc Nephrol 2001; 12: 2482-2489
24. Böhmig GA, Wahrmann M, Regele H, Exner M, Robl B, Derfler K,
Soliman T, Bauer P, Müllner M, Druml W: Immunoadsorption in
severe C4d-positive acute kidney allograft rejection: A randomized
controlled trial. Am J Transplant 2007;7:117-121
25. Gomes AM, Pedroso S, Martins LS, Malheiro J, Viscayno JR, Santos
J, Dias L, Henriques AC, Sarmento AM, Cabrita A: Diagnosis and
treatment of acute humoral kidney allograft rejection.Transplant Proc 2009; 41: 855-858
26. Gungor O, Sen S, Kircelli F, Yilmaz M, Sarsik B, Ozkahya M,
Hoscoskun C, Ok E, Toz H: Plasmapheresis therapy in renal
transplant patients: Five-year experience. Transplant Proc 2011; 43:
853-857
27. Ibernón M, Gil-Vernet S, Carrera M, Serón D, Moreso F, Bestard
O, Cruzado JM, Grinyó JM: Therapy with plasmapheresis and
intravenous immunoglobulin for acute humoral rejection in kidney
transplantation. Transplant Proc 2005; 37: 3743-3745
28. Rocha PN, Butterly DW, Greenberg A, Reddan DN, Tuttle-Newhall
J, Collins BH, Kuo PC, Reinsmoen N, Fields T, Howell DN,
Smith SR: Beneficial effect of plasmapheresis and intravenous
immunoglobulin on renal allograft survival of patients with acute
humoral rejection. Transplantation 2003; 75: 1490-1495
29. White NB, Greenstein SM, Cantafio AW, Schechner R, Glicklich
D, McDonough P, Pullman J, Mohandas K, Boctor F, Uehlinger
J, Tellis V: Successful rescue therapy with plasmapheresis and
intravenous immunoglobulin for acute humoral renal transplant
rejection. Transplantation 2004; 78: 772-774
30. Lehrich RW, Rocha PN, Reinsmoen N, Greenberg A, Butterly
DW, Howell DN, Smith SR: Intravenous immunoglobulin and
plasmapheresis in acute humoral rejection: Experience in renal
allograft transplantation. Hum Immunol 2005; 66: 350-358
31. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron
D, Hill GS, Glotz D, Suberbielle-Boissel C: Comparison of
combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg
in the treatment of antibody-mediated rejection. Am J Transplant
2009; 9: 1099-1107
32. Liu M, Ji SM, Tang Zh, Ji DX, Chen HP, Liu ZH, Li LS: C4dpositive
acute humoral renal allograft rejection: Rescue therapy
by immunoadsorption in combination with tacrolimus and mycophenolate mofetil. Transplant Proc 2004; 36: 2101-2103
33. Ulinski T: Recurrence of focal segmental glomerulosclerosis after
kidney transplantation: Strategies and outcome. Curr Opin Organ
Transplant 2010; 15: 628-632
34. Tsagalis G, Psimenou E, Nakopoulou L, Laggouranis A: Combination
treatment with plasmapheresis and rituximab for recurrent focal
segmental glomerulosclerosis after renal transplantation. Artif
Organs 2011; 35: 420-425
35. Davenport RD: Apheresis treatment of recurrent focal segmental
glomerulosclerosis after kidney transplantation: Re-analysis of
published case-reports and case-series. J Clin Apher 2001; 16:
175-178
36. Ponticelli C, Banfi G: Thrombotic microangiopathy after kidney
transplantation. Transpl Int 2006; 19: 789-794
37. Chiurchiu C, Ruggenenti P, Remuzzi G: Thrombotic
microangiopathy in renal transplantation. Ann Transplant 2002; 7:
28-33
38. Goplani KR, Vanikar AV, Shah PR, Gumber M, Feroz A, Patel HV,
Kasat P, Falodia J, Saboo D, Kaswaan K, Geerish MS, Pandya T,
Trivedi HL: Postrenal transplant hemolytic uremic syndrome/
thrombotic microangiopathy: Ahmedabad experience. Transplant
Proc 2008; 40: 1114-1116

Thank you for copying data from http://www.arastirmax.com